Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 14/20 | 0.56 |
| ▸ | MAOA | P21397 | 10/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536433 | 0.84 | MAOB (0.68) | GSTP1MAOBMAOACYP1A1CYP1A2 | |
| SCHEMBL23380165 | 0.77 | GSTP1 (0.42) | GSTP1CA1CA2CA9 | |
| SCHEMBL72587 | 0.76 | MAOB (0.56) | GSTP1MAOBMAOACYP1A1CYP1A2 | |
| SCHEMBL9155218 | 0.76 | GSTP1 (0.68) | GSTP1MAOBMAOACYP1A1CYP1A2 | |
| SCHEMBL13586765 | 0.76 | GSTP1 (0.41) | GSTP1CA1CA2CA9 | |
| SCHEMBL13586795 | 0.76 | GSTP1 (0.41) | GSTP1CA1CA2CA9 | |
| SCHEMBL13586792 | 0.76 | GSTP1 (0.41) | GSTP1CA1CA2CA9 | |
| SCHEMBL13586764 | 0.76 | GSTP1 (0.41) | GSTP1CA1CA2CA9 | |
| SCHEMBL13586758 | 0.76 | GSTP1 (0.41) | GSTP1CA1CA2CA9 | |
| SCHEMBL6671636 | 0.75 | ESR1 (0.42) | CYP1A1CYP1A2CYP1B1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3151919-B1 | CARBON MONOXIDE-RELEASING MOLECULES FOR THERAPEUTIC APPLICATIONS AND METHODS OF MAKING AND USING THEREOF | UNIV GEORGIA STATE RES FOUND (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2018093924-A1 | CARBON MONOXIDE-RELEASING MOLECULES AND THERAPEUTIC APPLICATIONS THEREOF | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20170128456-A1 | CARBON MONOXIDE-RELEASING MOLECULES FOR THERAPEUTIC APPLICATIONS AND METHODS OF MAKING AND USING THEREOF | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC, (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170128456-A1 | CARBON MONOXIDE-RELEASING MOLECULES FOR THERAPEUTIC APPLICATIONS AND METHODS OF MAKING AND USING THEREOF | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC, (US) | 2017-05-11 | — | — | US | disclosed |
| WO-2015191616-A1 | CARBON MONOXIDE-RELEASING MOLECULES FOR THERAPEUTIC APPLICATIONS AND METHODS OF MAKING AND USING THEREOF | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128456-A1 | CARBON MONOXIDE-RELEASING MOLECULES FOR THERAPEUTIC APPLICATIONS AND METHODS OF MAKING AND USING THEREOF | MB, CYC1, COX15 | GSTP1 2312/4885MAOB 504/4885MAOA 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.